News

Entresto, earlier known as LCZ696, will be available to treat adult patients with symptomatic chronic heart failure and reduced ejection fraction (HfrEF) after final approval from the European

Praluent, which is being developed by Sanofi and Regeneron Pharmaceuticals, will be available in both a 75 mg and 150 mg dose for self-administration every two weeks. It

According to the Centers for Disease Control and Prevention, approximately 21 million people in the United States have been diagnosed with diabetes. Over time, diabetes increases the risk

The Accurin drug candidate is intended at treating solid tumors. The actively targeted Accurin is designed to impart cellular targeting capability. Pfizer’s decision results in a $2.5m payment

MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1), an immunomodulatory enzyme, is required for the effective triggering of an immune response. However, dysregulation of MALT1 is also associated

Atlas joins previous seed investors Forbion Capital Partners (Forbion) and Omega Funds (Omega) as investors in this funding round. Replimune, headquartered in Oxford UK and with a significant

The Clinical Trial Application (CTA) for XEN801 was accepted by Health Canada and the first patient has been dosed in the Phase 1 clinical trial. If supported by

Mylan, Amneal Pharmaceuticals, Roxane Laboratories, Actavis and Sandoz had filed abbreviated new drug applications (ANDAs) to market generic versions of Vyvanse. Following the drug makers’ plan to create

The institute granted the funding under its CIRM 2.0 program, which is designed to speed up the development of stem cell-based treatments for people with unmet medical requirements.